読み込み中
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
前日終値
$1.02
−$0.02 · -1.92%
時間外
$1.0378
+$0.0178 · +1.75%
10月8日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
日中レンジ
現在 $1.02
52週レンジ
現在 $1.02
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
43
適正価値
センチメント
54
まちまち
リスク
71
高リスク
モメンタム
63
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
日中レンジ
現在 $1.02
52週レンジ
現在 $1.02
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 3302.6万 USD | 3862.7万 USD | 4128.8万 USD | 4426.1万 USD | 3389.41万 USD |
| 売上原価 | 622.2万 USD | 710万 USD | 474.2万 USD | 509.8万 USD | 364.74万 USD |
| 粗利益 | 2680.4万 USD | 3152.7万 USD | 3654.6万 USD | 3916.3万 USD | 3024.67万 USD |
| 研究開発 | 2082.3万 USD | 2222.7万 USD | 2381.7万 USD | 1951.4万 USD | 1540.73万 USD |
| 販売・一般管理 | 4704万 USD | 5635.4万 USD | 5704.3万 USD | 4448.2万 USD | 3167.89万 USD |
| 営業費用 | 7208.9万 USD | 8272.4万 USD | 8484.5万 USD | 6652.4万 USD | 4843.53万 USD |
| 受取利息 | 726.7万 USD | 1014.2万 USD | 1037.6万 USD | 391.7万 USD | 15.08万 USD |
| 支払利息 | — | — | — | 12.69万 USD | 104.44万 USD |
| 減価償却費と償却費 | 514.2万 USD | 431.5万 USD | 456.6万 USD | 269.8万 USD | 142.39万 USD |
| 営業利益 | −4528.5万 USD | −5119.7万 USD | −4829.9万 USD | −2736.1万 USD | −1818.86万 USD |
| 純利益 | −4463万 USD | −4105.5万 USD | −3792.3万 USD | −2357.1万 USD | −1908.22万 USD |
会社概要が更新されました 2026年10月9日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$6.00
上昇余地（488.24%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI353.73万0.00%2.3兆 USD0.03%$379.56-0.39%
Vanguard Extended Market ETFVXF157.39万0.00%954億 USD0.05%$233.13-0.15%
Vanguard Health Care ETFVHT36.66万0.00%220億 USD0.09%$313.85-0.46%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM6万0.05%1.17億 USD0.73%$15.90-0.44%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFVanguard Health Care ETFVHTEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
